Clinical Trial Detail

NCT ID NCT02420717
Title Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

B-cell acute lymphoblastic leukemia

Therapies

Ruxolitinib

Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate

Dasatinib

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Cytarabine + Leucovorin + Methotrexate

Age Groups: child adult

No variant requirements are available.